Last Updated: November 16, 2026

Olaratumab - Biologic Drug Details

« Back to Dashboard


Summary for olaratumab
Tradenames:1
High Confidence Patents:2
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for olaratumab
Recent Clinical Trials for olaratumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Telix Pharmaceuticals (Innovations) Pty LtdPHASE1
University of MiamiPhase 1
Janssen Scientific Affairs, LLCPhase 1

See all olaratumab clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for olaratumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for olaratumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Eli Lilly And Company LARTRUVO olaratumab Injection 761038 8,128,929 2026-06-19 DrugPatentWatch analysis and company disclosures
Eli Lilly And Company LARTRUVO olaratumab Injection 761038 8,574,578 2031-10-19 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for olaratumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for olaratumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
311 50005-2017 Slovakia ⤷  Start Trial PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161111
LUC00012 Luxembourg ⤷  Start Trial PRODUCT NAME: OLARATUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (LARTRUVO); AUTHORISATION NUMBER AND DATE: EU/1/16/1143 20161111
620 Finland ⤷  Start Trial
C20170011 00211 Estonia ⤷  Start Trial PRODUCT NAME: OLARATUMAB;REG NO/DATE: EU/1/16/1143 11.11.2016
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Olaratumab Market Dynamics, Financial Trajectory, Regulatory Withdrawal, and Patent Outlook

Last updated: September 14, 2026

Olaratumab, marketed as Lartruvo by Eli Lilly, generated rapid sales after its accelerated FDA approval in October 2016 but lost its commercial market after the confirmatory ANNOUNCE trial failed to verify clinical benefit. The FDA withdrew approval in June 2019, and Lilly discontinued global commercialization. Olaratumab has no active U.S. commercial market, no established generic or biosimilar launch pathway, and limited residual value outside historical litigation, regulatory, and clinical-development analysis.

What was olaratumab approved to treat?

Olaratumab was a recombinant human monoclonal antibody targeting platelet-derived growth factor receptor alpha, or PDGFR-alpha. The FDA approved it in combination with doxorubicin for adults with advanced soft-tissue sarcoma that was not amenable to curative surgery or radiotherapy and for which an anthracycline-containing regimen was appropriate.

The October 2016 approval used the accelerated approval pathway. The pivotal basis was a randomized phase 2 study showing a progression-free survival and overall-survival signal in patients treated with olaratumab plus doxorubicin compared with doxorubicin alone. The regimen was not approved as monotherapy.

Item Olaratumab status
Brand Lartruvo
Active ingredient Olaratumab
Developer and marketer Eli Lilly and Company
Target PDGFR-alpha
Initial FDA approval October 19, 2016
FDA pathway Accelerated approval
Indication Advanced soft-tissue sarcoma
Combination partner Doxorubicin
Dosage form Intravenous infusion
Confirmatory trial ANNOUNCE, phase 3
U.S. approval status Withdrawn
Current commercial status Discontinued

The approval was unusual because the confirmatory trial failed to reproduce the earlier survival result. That failure eliminated the clinical and commercial foundation of the product.

When did olaratumab lose exclusivity and market access?

Olaratumab lost market access before ordinary patent or biologic exclusivity expiration. Lilly announced in January 2019 that ANNOUNCE had failed to meet its primary overall-survival endpoint in the overall soft-tissue-sarcoma population and in the leiomyosarcoma subgroup. Lilly and regulators advised against starting new patients.

The FDA later withdrew the approval. The European Medicines Agency recommended suspension of the marketing authorization, and the European Commission subsequently revoked the authorization in 2019.

Date Event
October 2016 FDA grants accelerated approval for Lartruvo plus doxorubicin
2017 Commercial launch expands in the United States and other markets
January 2019 Lilly reports negative ANNOUNCE results
January-February 2019 Regulators advise that new patients should not begin treatment
April 2019 EMA recommends suspension of the European authorization
June 2019 FDA withdraws U.S. approval
2019 Lilly ends routine commercial supply and global commercialization

The biologic exclusivity period did not determine the product’s market life. Under the Biologics Price Competition and Innovation Act, a reference biologic can receive 12 years of reference-product exclusivity from first licensure, subject to statutory limitations. Olaratumab’s commercial failure occurred roughly three years after approval, long before that period could have supported meaningful biosimilar competition.

What was the financial trajectory of Lartruvo?

Lartruvo had a short, steep revenue curve. Sales increased rapidly after launch because the product entered a high-unmet-need oncology market with an accelerated approval and a favorable early survival signal. Revenue then fell after the ANNOUNCE failure and regulatory withdrawal.

Eli Lilly’s annual reports identified Lartruvo as a product with material sales growth during the initial launch period. Reported sales were approximately:

Fiscal year Approximate Lartruvo revenue Market interpretation
2016 About $25 million Partial launch year
2017 About $100 million Initial commercial adoption
2018 About $300 million Peak commercial period
2019 Sharp decline Withdrawal, treatment discontinuation, and inventory effects
2020 onward No meaningful recurring commercial franchise Product discontinued

The exact reported amount can differ depending on whether a source uses gross product revenue, net revenue, geographic presentation, or later accounting adjustments. The central financial pattern is clear: Lartruvo moved from launch-stage revenue to peak revenue in 2018, then suffered a rapid collapse after the confirmatory trial failure.

The revenue profile reflected several factors:

  1. The soft-tissue-sarcoma population was relatively small.
  2. The regimen was restricted to patients suitable for doxorubicin.
  3. Treatment required intravenous administration.
  4. The product depended on accelerated-approval evidence.
  5. The negative phase 3 result removed physician confidence and reimbursement support.

The product’s failure also affected Lilly’s pipeline economics. Development spending, manufacturing capacity, commercial infrastructure, medical-affairs activity, and inventory associated with the antibody had limited recoverable value after withdrawal.

What caused the collapse in olaratumab demand?

The ANNOUNCE trial was the decisive commercial event. The study did not confirm the overall-survival improvement observed in the phase 2 trial. It also failed to show the expected benefit in the leiomyosarcoma subgroup.

The study compared olaratumab plus doxorubicin with doxorubicin plus placebo. Its failure created three immediate commercial effects:

  • Physicians stopped initiating new patients.
  • Existing treatment decisions shifted toward established sarcoma regimens.
  • Payers and hospitals lost a rationale for routine reimbursement and formulary support.

This was a clinical-risk failure rather than a conventional price or competitor-driven erosion event. Olaratumab did not lose share because a lower-priced generic or biosimilar entered the market. It lost its market because the benefit-risk case no longer supported treatment.

What is the FDA regulatory status of olaratumab?

The FDA approval is withdrawn. Lartruvo is not an FDA-approved treatment for soft-tissue sarcoma.

The original approval was conditioned on verification of clinical benefit in a post-approval trial. When ANNOUNCE failed, the accelerated-approval basis was no longer sustainable. The FDA’s withdrawal action closed the U.S. regulatory pathway for routine marketing under the original indication.

Olaratumab is therefore distinct from products that remain approved but face patent expiry. Its regulatory status prevents a conventional generic-launch scenario. A company cannot rely on an abbreviated new drug application to market a copy of a withdrawn biologic under the former approval framework.

What patents protected olaratumab?

Olaratumab was protected through a combination of biologic exclusivity, antibody-related patent rights, manufacturing know-how, and regulatory data rights. Because olaratumab was regulated as a biologic, it did not have a conventional Orange Book patent profile comparable to a small-molecule drug such as imatinib or pazopanib.

The primary protection categories were:

Antibody and antigen-binding patents

These rights may cover:

  • Antibodies binding PDGFR-alpha;
  • Specific antibody sequences;
  • Complementarity-determining regions;
  • Binding characteristics;
  • Antibody variants and engineered forms.

Pharmaceutical composition and formulation patents

Potential claim areas include:

  • Olaratumab compositions;
  • Stabilized liquid formulations;
  • Buffer systems;
  • Concentration ranges;
  • Container and storage conditions;
  • Intravenous administration preparations.

Manufacturing and process rights

Manufacturing barriers may involve:

  • Recombinant cell-line production;
  • Cell-culture conditions;
  • Purification steps;
  • Viral-clearance processes;
  • Quality-control assays;
  • Aggregation control and potency testing.

Method-of-use rights

Method claims could cover use of an anti-PDGFR-alpha antibody with doxorubicin for soft-tissue sarcoma or related oncology settings. Such claims would have limited practical value after the confirmatory failure and withdrawal of the underlying indication.

A precise patent-by-patent expiration analysis requires verified patent-family records and claim-status review. Public regulatory materials establish the approval, withdrawal, and biologic-exclusivity framework, but they do not create an Orange Book-style consolidated list for all biologic patent rights.

What is the Orange Book status of olaratumab?

Olaratumab does not have a conventional Orange Book patent-listing position. Lartruvo was regulated as a biologic product, and biologic reference-product protection is handled through the BPCIA framework rather than the standard small-molecule Orange Book pathway.

The practical implications are:

  • No conventional Orange Book Paragraph IV certification strategy;
  • No standard ANDA-based generic substitution pathway;
  • No routine small-molecule patent-stay analysis under Hatch-Waxman;
  • Any follow-on product would need to proceed through a biologic or full-license pathway;
  • Withdrawal of the reference product’s approval eliminates the ordinary commercial basis for a biosimilar launch.

Were there Paragraph IV challenges to olaratumab?

No commercially significant Paragraph IV challenge is associated with olaratumab. The product’s market ended before patent litigation could become a material driver of generic entry.

A Paragraph IV strategy would have been structurally inappropriate for a conventional biologic product. A follow-on sponsor would instead consider the BPCIA pathway, including reference-product exclusivity, patent-exchange procedures, and potential patent litigation under the biologic framework.

No known generic or biosimilar competitor reached the U.S. market before Lartruvo was withdrawn.

What biosimilar risk existed for olaratumab?

The practical biosimilar risk was low because regulatory failure eliminated the market before biosimilar development could mature. The theoretical exclusivity window was longer than the product’s actual commercial life.

A biosimilar sponsor would have faced several barriers:

Barrier Commercial effect
Small soft-tissue-sarcoma population Limited addressable market
Combination with doxorubicin Complex clinical positioning
Failed confirmatory study Weak reference-product value
Withdrawn approval Uncertain regulatory and reimbursement pathway
Complex monoclonal-antibody manufacturing High development cost
Limited physician demand Poor return on biosimilar investment

Olaratumab illustrates that long regulatory exclusivity does not guarantee durable commercial protection. Clinical validation is a prerequisite for maintaining value in an accelerated-approval oncology franchise.

Which companies challenged or replaced olaratumab?

No company displaced Lartruvo through a direct generic or biosimilar launch. Instead, the competitive set consisted of established soft-tissue-sarcoma treatments and clinical-trial options.

Relevant alternatives included:

  • Doxorubicin-based chemotherapy;
  • Ifosfamide-containing regimens;
  • Gemcitabine and docetaxel;
  • Trabectedin;
  • Eribulin;
  • Pazopanib;
  • Clinical trials involving targeted agents and immunotherapies.

The closest commercial substitutes depended on histology, prior treatment, disease location, patient fitness, and treatment objective. Because olaratumab was withdrawn, competition shifted from product-level price competition to clinical substitution.

How strong was the olaratumab patent estate?

The patent estate may have provided meaningful technical and legal protection during the product’s short commercial period, but its economic strength was weakened by the failed clinical program.

Patent strength should be assessed across four dimensions:

Dimension Assessment
Composition and antibody claims Potentially strong if sequence-specific and technically narrow
Formulation claims Potentially useful against copycat products using the same formulation
Method-of-use claims Commercially weakened by withdrawal of the approved indication
Manufacturing know-how Difficult to copy but less valuable without market demand

The key distinction is between legal exclusivity and commercial exclusivity. Olaratumab may have retained patent or biologic protection after 2019, but those rights did not preserve revenue because the product no longer had regulatory or clinical support.

What generic launch scenarios existed for olaratumab?

The realistic launch scenarios were limited:

  1. No conventional generic launch under the ANDA pathway.
  2. No biosimilar launch before market withdrawal.
  3. Possible future development of an antibody against the same target under a separate regulatory strategy.
  4. Limited off-label or investigational use, subject to clinical and institutional decisions.
  5. No credible commercial opportunity without a new validated indication.

A follow-on company would need to establish a new clinical and regulatory value proposition. Patent clearance alone would not solve the central problem created by the negative ANNOUNCE result.

Did licensing deals affect olaratumab’s commercial value?

Olaratumab was developed and commercialized by Eli Lilly. No major external licensing transaction became a defining element of its commercial trajectory. The product originated from Lilly’s oncology development activities and was marketed through Lilly’s commercial infrastructure.

The lack of a large external transaction reduced the possibility of transferring the failed asset to a buyer seeking residual value. After the regulatory withdrawal, the asset’s value was primarily limited to:

  • Archived clinical data;
  • Manufacturing knowledge;
  • Antibody technology;
  • Potential research use;
  • Historical evidence for accelerated-approval risk management.

What litigation affected olaratumab?

No major patent or commercial litigation drove the product’s market outcome. The primary event was regulatory and clinical, not judicial.

The relevant legal exposure centered on:

  • The FDA’s withdrawal of approval;
  • Product labeling and treatment guidance;
  • Potential reimbursement disputes;
  • Contractual and inventory matters following discontinuation;
  • Any shareholder or securities claims arising from disclosure of trial results.

No sustained Hatch-Waxman litigation cycle developed because the product did not reach the point of conventional generic competition.

How does olaratumab compare with successful oncology biologics?

Olaratumab differed from durable oncology biologics in four ways:

Factor Olaratumab Durable oncology biologics
Evidence base Accelerated approval followed by failed confirmation Confirmed benefit maintained
Indication breadth Narrow soft-tissue-sarcoma use Often multiple indications
Commercial scale Small specialty population Broader or expanding populations
Competitive durability Ended after clinical failure Extended through new indications and lifecycle management

Products such as trastuzumab, pembrolizumab, and nivolumab expanded through multiple indications and sustained development programs. Olaratumab had no comparable lifecycle-management opportunity after ANNOUNCE failed.

What is the current commercial outlook for olaratumab?

The current commercial outlook is effectively zero for routine marketed sales. Olaratumab is a discontinued product with no active U.S. approval and no established biosimilar competition.

Its remaining relevance is analytical:

  • It is a case study in accelerated-approval risk.
  • It illustrates the difference between patent exclusivity and commercial durability.
  • It demonstrates the financial impact of a negative confirmatory oncology trial.
  • It remains relevant to valuation models for biologics with narrow indications.
  • It provides a warning against treating early survival signals as durable franchise value.

Key Takeaways

  • Olaratumab, marketed as Lartruvo, was FDA-approved in 2016 for advanced soft-tissue sarcoma with doxorubicin.
  • Lilly’s sales rose from launch-stage revenue to approximately $300 million in 2018 before collapsing after the ANNOUNCE trial failed.
  • The FDA withdrew approval in 2019, and Lilly discontinued global commercialization.
  • No meaningful Paragraph IV litigation or biosimilar competition developed.
  • Olaratumab did not follow a conventional Orange Book generic-erosion cycle.
  • The product lost commercial value because of clinical failure, not because of patent expiry.
  • Its patent and manufacturing rights may have remained legally relevant, but they could not preserve market demand.
  • The asset has no current routine commercial franchise.

FAQs About Olaratumab

Is olaratumab still available in the United States?

No. The FDA withdrew approval, and Lilly discontinued routine commercial distribution.

Why did the FDA withdraw Lartruvo?

The FDA withdrew Lartruvo after the required ANNOUNCE confirmatory trial failed to verify the survival benefit supporting accelerated approval.

Did a generic version of olaratumab launch?

No conventional generic or biosimilar version achieved commercial launch before the product was withdrawn.

Was olaratumab a PDGFR inhibitor?

Olaratumab was a monoclonal antibody directed against PDGFR-alpha. It was not a small-molecule kinase inhibitor.

What happened to patients already receiving Lartruvo?

Regulators advised against starting new patients after the negative trial results. Treatment decisions for patients already receiving therapy were handled by treating physicians based on clinical circumstances and available alternatives.

References

  1. European Medicines Agency. (2019). EMA recommends suspension of marketing authorisation for Lartruvo. https://www.ema.europa.eu/

  2. Eli Lilly and Company. (2017). 2016 annual report. https://investor.lilly.com/

  3. Eli Lilly and Company. (2018). 2017 annual report. https://investor.lilly.com/

  4. Eli Lilly and Company. (2019). 2018 annual report. https://investor.lilly.com/

  5. Food and Drug Administration. (2016). FDA approves Lartruvo for soft tissue sarcoma. https://www.fda.gov/

  6. Food and Drug Administration. (2019). FDA statement on the voluntary withdrawal of Lartruvo. https://www.fda.gov/

  7. Food and Drug Administration. (2020). Withdrawal of approval of new drug application for Lartruvo. Federal Register. https://www.federalregister.gov/

  8. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009. Public Law 111-148, §7002. https://www.congress.gov/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.